ERBB2 and breast cancer: The analyses showed significant differences between the two groups concerning plasma cells (p = 0.014), memory resting CD4+ T-cells (p < 0.001) and resting mast cells (p < 0.001), with a consistent higher expression in HER2-positive BC (Fig. 2).